198 related articles for article (PubMed ID: 28732324)
1. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
[TBL] [Abstract][Full Text] [Related]
2. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
3. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy.
Fréour T; Barrière P; Masson D
Eur J Cancer; 2017 Mar; 74():1-8. PubMed ID: 28135602
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
Furlanetto J; Marmé F; Seiler S; Thode C; Untch M; Schmatloch S; Schneeweiss A; Bassy M; Fasching PA; Strik D; Stickeler E; Schem C; Karn T; Grischke EM; Denkert C; van Mackelenbergh M; Müller V; Nekljudova V; Loibl S
Eur J Cancer; 2021 Jul; 152():193-203. PubMed ID: 34116270
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA; Cameron DA
J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study.
Ünal Ç; Ordu Ç; Özmen T; İlgun AS; Çelebi F; Baysal B; Özkurt E; Duymaz T; Erdoğan İyigün Z; Kurt S; Öztürk MA; Pilancı KN; Alço G; Yararbaş K; Kayan Tapan T; Güven DC; Soybir G; Özmen V
Curr Oncol; 2023 Oct; 30(10):9217-9229. PubMed ID: 37887566
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
Wang S; Pei L; Hu T; Jia M; Wang S
Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
[TBL] [Abstract][Full Text] [Related]
8. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer.
Perdrix A; Saint-Ghislain M; Degremont M; David M; Khaznadar Z; Loeb A; Leheurteur M; Di Fiore F; Clatot F
Reprod Biomed Online; 2017 Oct; 35(4):468-474. PubMed ID: 28652099
[TBL] [Abstract][Full Text] [Related]
9. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
Wang SY; Wang S
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
[TBL] [Abstract][Full Text] [Related]
10. Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram.
Barnabei A; Strigari L; Marchetti P; Sini V; De Vecchis L; Corsello SM; Torino F
Oncologist; 2015 Oct; 20(10):1111-8. PubMed ID: 26341758
[TBL] [Abstract][Full Text] [Related]
11. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
[TBL] [Abstract][Full Text] [Related]
12. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
Fornier MN; Modi S; Panageas KS; Norton L; Hudis C
Cancer; 2005 Oct; 104(8):1575-9. PubMed ID: 16134178
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
Anders C; Marcom PK; Peterson B; Gu L; Unruhe S; Welch R; Lyons P; Behera M; Copland S; Kimmick G; Shaw H; Snyder S; Antenos M; Woodruff T; Blackwell K
Cancer Invest; 2008; 26(3):286-95. PubMed ID: 18317970
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
Anderson RA; Kelsey TW; Perdrix A; Olympios N; Duhamel O; Lambertini M; Clatot F
Breast Cancer Res Treat; 2022 Apr; 192(2):273-282. PubMed ID: 34997365
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
[TBL] [Abstract][Full Text] [Related]
17. Ovarian reserve in premenopausal women with breast cancer.
Zong X; Yu Y; Chen W; Zong W; Yang H; Chen X
Breast; 2022 Aug; 64():143-150. PubMed ID: 35691250
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Anti-Müllerian Hormone and Inhibin B in Patients with Premenopausal Hormone Receptor-positive Breast Cancer.
Kim HA; Seong MK; Kim JH; Kim YG; Choi HS; Kim JS; Park IC; Jin HO; Lee JK; Noh WC
Anticancer Res; 2016 Mar; 36(3):1051-7. PubMed ID: 26976997
[TBL] [Abstract][Full Text] [Related]
19. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
